Portage Biotech (NASDAQ: PRTG) is one of 268 publicly-traded companies in the “Crude petroleum & natural gas” industry, but how does it compare to its peers? We will compare Portage Biotech to related companies based on the strength of its risk, profitability, analyst recommendations, dividends, valuation, earnings and institutional ownership.
Institutional and Insider Ownership
7.1% of Portage Biotech shares are held by institutional investors. Comparatively, 48.6% of shares of all “Crude petroleum & natural gas” companies are held by institutional investors. 11.0% of shares of all “Crude petroleum & natural gas” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Portage Biotech and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Portage Biotech Competitors||2104||10499||15057||514||2.50|
Portage Biotech currently has a consensus price target of $35.00, suggesting a potential upside of 59.53%. As a group, “Crude petroleum & natural gas” companies have a potential upside of 13.04%. Given Portage Biotech’s stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than its peers.
This table compares Portage Biotech and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Portage Biotech Competitors||-32.98%||-38.93%||4.07%|
Earnings & Valuation
This table compares Portage Biotech and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Portage Biotech||N/A||-$15.83 million||-16.25|
|Portage Biotech Competitors||$5.49 billion||-$638.49 million||-4.67|
Portage Biotech’s peers have higher revenue, but lower earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.